source
- Rezdiffra Beats Wall Street Forecasts as MASH Market ExpandsRezdiffra, a drug candidate targeting metabolic dysfunction‑associated steatohepatitis (MASH), is outperforming analysts' expectations according to recent commentary. The optimism comes as the mar…
- Dr. Silbermann highlights trial design priorities for multiple myeloma, from supportive care to diverse enrollmentDr. Rebecca Silbermann, an associate professor at Oregon Health & Science University, outlined key considerations for designing multiple myeloma clinical trials. She stressed the importance of alig…